Feasibility assessment of the newest domestic anthelmintics development taking into account the existing drug range
DOI:
https://doi.org/10.24959/uekj.20.11Keywords:
market analysis, range, anthelmintic drugsAbstract
The development of high quality and affordable medicines inUkraineis an important area of the work of modern pharmacy within the import substitution policy.
Aim. To determine the feasibility of developing a domestic drug for the treatment of helminthiases of the digestive system by evaluating the existing range of anthelmintic drugs presented on the pharmaceutical market ofUkraine.
Results. Analysis of the available anthelmintic medicines range as of February 5, 2020, according to the data of the State Register of Medicines of Ukraine, showed that drugs of Р02В group (medicines used trematodoses for trematodoses treatment) are absent on the pharmaceutical market of Ukraine, and the available medicines are presented exclusively by monopreparations. The vast majority of drugs are made on the basis of albendazole and pyrantel substances, while the share of the drugs are produced on the basis of mebendazole, piperazine, and levamisole is much smaller. There are some discrepancies in determining the manufacturer of the medicinal product. Thus, the applicant producers are dominated by representatives of theUnited Kingdom,France andHungary, and the actual producers are those ofFrance,India andRomania. At the same time, the distribution of drugs both by manufacturers-applicants and by actual manufacturers corresponds to the preference for foreign drugs, while domestic manufacturers offer fewer anthelminthic drugs. Tablets and oral suspensions dominate among the presented dosage forms of anthelmintic drugs.
Conclusions. According to the results of the market analysis of drugs for helminthiases treatment, it can be argued that the existing range does not fully meet the needs of the population of Ukraine for anthelmintic agents. It is advisable to develop the newest domestic anthelmintic drugs based on those substances that are included in the list of drugs of choice of the current protocols for helminthiases treatment. Particularly noteworthy is the complete absence of the P02B group drugs at the domestic pharmaceutical market, which indicates the urgency of the development of modern domestic anthelmintic drugs on the basis of appropriate substances. It is rational to combine several substances in order to obtain a wide range of pharmacological activity and synergies of substances, because today’s pharmaceutical market is represented exclusively by monotherapies.References
Dudnik, V. M., Iziumets, O. I., Laiko, L. I., Korolova, N. D., Kondratiuk, L. M., Rudenko, H. M., Ivaniuk, L. M. (2011). Diahnostyka i patohenetychni aspekty likuvannia helmintoziv. Sovremennaia pedyatryia, 4(38), 70–72.
Yershova, I. B., Osychniuk, L. M., Mochalova, H. O. (2013). Helmintozy u ditei Perynatolohyia y pedyatryia, 2(54), 125–131.
Samura, B. A., Babak, Yu. M., Kolesnyk, Yu. M. (Eds.). (2010). Farmakoterapyia : ucheb. dlia stud. vuzov: 4-e yzd., pererab y dop. Kharkiv: Zolotye stranytsy, 800.
Shadrin, O. H., Kovalchuk, A. A., Diukareva, S. V. Polkovnychenko L. M. (2015). Stan shlunkovo-kyshkovoho traktu ta shliakhy korektsii yoho porushen pryhelmintozai u ditei. Sovremennaia pedyatryia, 8(72), 88–91.
Avdiukhina, T. I., Konstantinova, T. N. Prokosheva, M. N. (2011). Sovremennyi vzgliad na problemu gelmintozov u detei i effektivnye puti ee resheniia. Sovremennaia pediatriia, 1(35), 73–77.
Herasymenko, S. S., Holovach, A. V., Yerina, A. M. (Eds.). (2000). Statystyka : pidruch. (2-edition). Kyiv: KNEU, 467.
Mostovyi, H. I., Dihtiar, A. O., Harkavyi, V. K. (2002). Teoriia statystyky : navch. posib. Karkiv: Vyd-vo Khar RI UA DU «Mahistr», 300.
Nastanova 00020. Askarydoz. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00020&format=pdf
Nastanova 00019. Hostryky (enterobioz). (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00019&format=pdf
Nastanova 00021. Kyshkovi tsestodozy. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm00021&format=pdf
Nastanova 01039. Nematodozy. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01039&format=pdf
Nastanova 01038. Stronhiloidoz. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01038&format=pdf
Nastanova 01043. Trykhotsefaloz. (n.d.). Available at: http://guidelines.moz.gov.ua/documents/2918?id=ebm01043&format=pdf
Downloads
Published
Issue
Section
License
Copyright (c) 2020 National University of Pharmacy
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
